Type A Aortic Dissection Clinical Trial
— CHINAOfficial title:
Multi-center, Randomized, Controlled Clinical Trial of BioGlue Surgical Adhesive as an Adjunct for Structural Repair and Hemostasis in Chinese Patients With Acute Type A Aortic Dissections.
Verified date | May 2020 |
Source | CryoLife, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A multi-center, randomized, controlled clinical trial is designed to investigate the safety and efficacy of BioGlue as an adjunct for structural repair and hemostasis to traditional surgical repair in Chinese subject with Acute type A aortic dissections.
Status | Active, not recruiting |
Enrollment | 202 |
Est. completion date | November 2020 |
Est. primary completion date | June 24, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Male or female subjects 18-70 years of age. - Subject has a confirmed diagnosis of acute type A aortic dissection with subtype A2. - Subject is willing and able to give written consent for the trial. If the subject is unconscious or under the influence of medications which render him or her unable to give fully informed consent, a guardian may provide informed consent for the subject regarding trial participation. Exclusion Criteria: - Subjects with known allergy to albumin, bovine products, or glutaraldehyde. - Subjects who have been treated with an investigational product who have not completed the entire follow-up period. - Subjects who do not meet the eligibility criteria, including those who do not wish to participate or give informed consent for trial participation, will not be enrolled into the trial, and will be offered equivalent, non-trial surgical or other treatment, as judged appropriate by the investigator. - Subjects with previous cardiac and aortic surgery. - End stage malperfusion syndromes (i.e. end-organ failure such as coma, paraplegia, hemiplegia, intestinal necrosis, or hepatic failure). - Subjects with Marfan syndrome or other connective tissue disorders. - Previous chronic dissections resulting from non-cardiac surgery and/or trauma. - Concomitant surgery of valve replacement (both in screening and intraoperative). |
Country | Name | City | State |
---|---|---|---|
China | Beijing Anzhen Hospital, Capital Medical University | Beijing | |
China | Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School | Nanjing | |
China | Nanjing First Hospital | Nanjing | |
China | Changhai Hospital,The Second Military Medical University | Shanghai | |
China | Zhongshan Hospital, Fudan University | Shanghai | |
China | Wuhan Asia Heart Hospital | Wuhan | |
China | Henan Provincial People's Hospital | Zhengzhou |
Lead Sponsor | Collaborator |
---|---|
CryoLife, Inc. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Successful Closure of the False Lumen | Successful closure of the false lumen as determined by intraoperative TEE. With successful closure of the false lumen, a complete disappearance of the false lumen will be achieved. | This success can be visually confirmed intraoperatively with a TEE (binary yes/no expression for each subject) | |
Secondary | Successful closure of the false lumen by CTA or TTE at discharge | Successful closure of the false lumen at discharge or at 20 days (+/- 10 days) post-operatively confirmed by CTA scan or Transthoracic Echocardiogram (TTE) scan if the subject is unable to have a CTA. | CTA or TTE scan at discharge or at 20 days (+/- 10 days) post-operatively for subjects with longer hospital stays. | |
Secondary | Time to repair the sinuses of Valsalva | During the operation the time to repair the sinuses of Valsalva will be recorded. | The time for repairing the sinuses of Valsalva will be documented intraoperatively. | |
Secondary | Evaluate the successful hemostasis at the anastomotic site | Hemostasis is assessed visually (i.e. lack of any observable extravascular bleeding) and is monitored until hemostasis is achieved at each applied anastomotic site. | The measurement begins intraoperatively after either BioGlue or Traditional Surgical Repair is applied to the anastomotic suture line(s) and the bypass cross clamp is released. | |
Secondary | Treatment failure of the aortic dissection repair site identified in "The CHINA Trial" which leads to either post-discharge mortality or re-operation. | Post-operative mortality and re-operation(s) will be collected from the subjects' medical charts retrospectively and during informed consent telephone notification. | The measurement begins at discharge and will end when the retrospective chart review is performed by the hospital (could be up to 3 years post-op) | |
Secondary | Proportion of subjects with device-related or procedure-related adverse events, determined by the investigators. | Post-operative adverse event(s) will be collected from the subjects' medical charts retrospectively. Assessment will only be performed on the surgical site from "The CHINA Trial," defined as obliteration of the false lumen (BioGlue group) or repair of acute type A aortic dissection (control group) and anastomosis (both BioGlue and control groups). | The measurement begins at discharge and will end when the retrospective chart review is performed by the hospital (could be up to 3 years post-op). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06199401 -
Safety and Efficacy of XJ-Procedure in Patients With Acute Type A Aortic Dissection Surgery
|
N/A | |
Completed |
NCT05751200 -
Safety and Efficacy of Aortic Root Reinforcement Combined With Vascular Grafts Eversion and built-in Procedure (XJ-procedure) in Patients With Acute Type A Aortic Dissection (ADVANCED-XJ )
|
||
Completed |
NCT04711889 -
Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Ulinastatin) II
|
N/A | |
Recruiting |
NCT03607786 -
Antegrade Cerebral Perfusion and Retrograde Inferior Vena Caval Perfusion for Total Aortic Arch Replacement
|
N/A | |
Completed |
NCT06415630 -
Prediction Models for Postoperative Reintubation in Patients With Acute Aortic Dissection
|
||
Enrolling by invitation |
NCT05927090 -
Outcomes of Type A Aortic Dissection Repair
|
||
Completed |
NCT05346497 -
Surgical Management of the Aortic Root and Long-term Outcomes For Acute Type A Aortic Dissection
|
||
Active, not recruiting |
NCT04831073 -
European Registry of Type A Aortic Dissection
|
||
Recruiting |
NCT06434987 -
Impact of RIVP on GI Function in Patients Undergoing Surgical Repair for ATAAD
|
||
Completed |
NCT02164201 -
Post Market Surveillance Study Evaluating BioFoam Surgical Matrix in Cardiovascular Surgery
|
N/A | |
Recruiting |
NCT04032366 -
iNO as Salvage Treatment of Hypoxemia After TAAD Surgery
|